Foresee offloads MMP-12 inhibitors in $584M deal, focuses on Camcevi's potential
Fuente:
FierceBiotech
Foresee Pharmaceuticals has sold a chunk of its clinical-stage pipeline in order to focus on the potential of its prostate cancer med Camcevi.